Ozan Yazıcı

Gazi, 06500, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 97 publications

A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing.

A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing.

Journal: Future oncology (London, England)

Published: August 04, 2026

Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study.

Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 14, 2026

Real-World 30-Day Mortality After the Last Dose of Immune Checkpoint Inhibitors: A Multicenter Retrospective Cohort Study in Turkey.

Real-World 30-Day Mortality After the Last Dose of Immune Checkpoint Inhibitors: A Multicenter Retrospective Cohort Study in Turkey.

Journal: Current oncology (Toronto, Ont.)

Published: May 17, 2026

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Journal: Cancers

Published: May 12, 2026

Regarding: Nachira D, Calabrese G, Bertolaccini L, et al. Oncological outcomes and prognostic factors of pulmonary metastasectomy in pancreatic cancer : Updates in Surgery, 2026, https://doi.org/10.1007/s13304-026-02605-x.

Regarding: Nachira D, Calabrese G, Bertolaccini L, et al. Oncological outcomes and prognostic factors of pulmonary metastasectomy in pancreatic cancer : Updates in Surgery, 2026, https://doi.org/10.1007/s13304-026-02605-x.

Journal: Updates in surgery

Published: April 26, 2026

Key Methodological Considerations in the Interpretation of the CONKO-007 Trial.

Key Methodological Considerations in the Interpretation of the CONKO-007 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 02, 2026

Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure.

Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure.

Journal: Breast (Edinburgh, Scotland)

Published: January 21, 2026

Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure.

Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure.

Journal: Breast (Edinburgh, Scotland)

Published: January 21, 2026

Immunomodulatory Effect of First-Line Cisplatin Versus Carboplatin in Response to Second-Line Nivolumab Therapy in Metastatic Non-Small Cell Lung Cancer.

Immunomodulatory Effect of First-Line Cisplatin Versus Carboplatin in Response to Second-Line Nivolumab Therapy in Metastatic Non-Small Cell Lung Cancer.

Journal: Cancer investigation

Published: December 26, 2025

Clinicopathological features and treatment outcomes of patients with fibrolamellar hepatocellular carcinoma: a retrospective multicenter study.

Clinicopathological features and treatment outcomes of patients with fibrolamellar hepatocellular carcinoma: a retrospective multicenter study.

Journal: Annals of Saudi medicine

Published: August 03, 2025

Compatibility of different PET/CT criteria in evaluating treatment response and survival in non-small cell lung cancer patients treated with immunotherapy.

Compatibility of different PET/CT criteria in evaluating treatment response and survival in non-small cell lung cancer patients treated with immunotherapy.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: May 27, 2025

Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group.

Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group.

Journal: International journal of cancer

Published: May 16, 2025

Showing 1-12 of 97

Last Updated: 09/26/2026